ClinicalTrials.gg
Not yet recruitingNCT07075133TIMEDIABUpdated Jun 1, 2026

Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes

An interventional study of Antidiabetic diet (control) and eTRE diet in Obesity, Sarcopenia and Post Menopause, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 45 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Obesity by University Hospital, Toulouse — 6 open to participants now, 6 under way, none of them phase 3. Obesity · University Hospital, Toulouse.

Planned enrollment
7th of 15
45 · median 38
Started
2026
the only one that year
No phase
12 of 18
3 open now
Registered
17th of 18
by date

Among the 18 studies in Obesity by University Hospital, Toulouse, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 17th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 18 studies in Obesity by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Obesity by University Hospital, Toulouse, or all of them as a file.
02

Study summary

The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint

Read the detailed description

Overweight, obesity, aging and menopause are all independent risk factors in the development of type 2 diabetes mellitus (T2DM). Older women with T2DM are at especially high risk for sarcopenia, i.e. loss of skeletal muscle mass and force, and cardiovascular diseases. The first line of T2DM treatment is based on lifestyle changes including weight loss and physical activity. One major current medical challenge is to find novel lifestyle therapies able to reduce cardiometabolic risk while perserving muscle mass in obese older individuals. As a result, intermittent fasting approaches, including time-restricted feeding/eating (TRF/TRE), have been offered as alternative dietary strategies that may have beneficial effects on weight control and T2DM. It has been recently observed that long-term TRF improve glucose homeostasis while perserving muscle mass and force in female obese mice. The purpose of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on various components of muscle health as primary endpoint, and blood glucose control, body composition, energy balance, cardiovascular risk, and metabolic health as secondary endpoints. This study will pave the way to larger scale randomized clinical trials investigating the long-term effects/benefits of such intervention and in other target populations.

03

Conditions studied

  • Obesity
  • Sarcopenia
  • Post Menopause
  • Type 2 Diabetes
  • Circadian Clock

Keywords

  • Timing of eating
  • Timing of exercise
  • Muscle Function
  • Metabolic Health
  • Obesity
  • Menopause
  • women
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (amenorrhea for at least 12 months, confirmed by gonadotrophins measures)
  • Age range 45-70 years
  • T2DM diagnosed for more than 1 year
  • Subjects with T2DM treated with lifestyle control alone or associated with metformine ± DPP4 inhibitors
  • Ability to sign written before any study-specific procedure
  • Subject considered as reliable and capable of adhering to protocol
  • Subjects with (BMI)≥ 30 kg/m²
  • Baseline eating period ≥ 14 h per day (as estimated by 95% eating interval)

Exclusion criteria

Exclusion Criteria:

  • Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea)
  • Subjects with > 8%
  • Subjects with any of the following medical conditions:

    • Congestive cardiac failure
    • Stage 4 chronic kidney disease (i.e. \< 30 ml/min/1.73 m2)
    • Liver cirrhosis or chronic liver disease
    • Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study
  • Subjects with previous or present history of serious eating disorder
  • Subjects not able to understand the form or fasting diary instructions
  • Subjects currently participating or has participated in another study of an medication or an investigational medical device within the last 30 days
  • Women with menopause hormone replacement therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Diet control (no chrono restriction) + exercise performed in the morning

    Patients following a standard antidiabetic diet combined with morning exercise

    Other: Antidiabetic diet (control) · Other: Physical activity in the morning

  • Experimental
    eTRE (chrono restriction) + exercise performed in the morning

    Patients following the eTRE program combined with physical exercise performed in the morning

    Other: eTRE diet · Other: Physical activity in the morning

  • Experimental
    eTRE (chrono restriction) + exercise performed in the afternoon

    Patients following the eTRE program combined with physical exercise performed in the afternoon

    Other: eTRE diet · Other: Physical activity in the afternoon

Interventions

  • OtherAntidiabetic diet (control)

    Standard antidiabetic diet

  • OthereTRE diet

    eTRE for a total duration of 12 weeks. During the eTRE, volunteers will have to eat and drink (meals + snacks, medication) exclusively during an 8-hour period which will extend between 6 a.m. (flexible: or 7 a.m. or 8 a.m.) in the morning and 2 p.m. (depending on the chosen start time: or 3 p.m. or 4 p.m.), which corresponds to a fasting period of 16 hours per day

  • OtherPhysical activity in the morning

    Physical exercise will consist of 3 weekly morning sessions that will combine aerobic and resistance exercises

  • OtherPhysical activity in the afternoon

    The physical exercise will consist of 3 weekly afternoon sessions that will combine aerobic and resistance exercises.

06

What researchers measure

Primary outcomes

  1. Change in skeletal muscle function

    Change in skeletal muscle function, assessed by 30-CTS score at inclusion (baseline) and 12 weeks after diet/exercise program; This test is used to assess lower limb strength. The score corresponds to the total number of standing positions correctly performed within the allotted 30 seconds.

    Time frame: 4 years

Secondary outcomes

  1. Change in muscle function

    Change in muscle function assessed by various tests, such as: \- TUG Score ( calculates the time it takes to get up from a chair without using your arms. A time \<10 seconds is normal; 10\>time\<20 is a marker of frailty; time \<20 seconds:the elderly person is at high risk of falling).

    Time frame: 4 years

  2. • Change in M value measured by hyperinsulinemic euglycemic clamp

    Systemic insulin sensitivity will be assessed using a euglycemic hyperinsulinemic clamp, oral hyperglycemia, and insulin signaling pathway studies. The M value (unitless measurement) determined during the clamp will be the marker of systemic insulin sensitivity.

    Time frame: 4 years

  3. Change in HbA1c, during an oral glucose tolerance test

    Change in HbA1c (in percentage), during an oral glucose tolerance test

    Time frame: 4years

  4. Change in fasting glucose, during an oral glucose tolerance test

    Change in fasting glucose (g/l), during an oral glucose tolerance test

    Time frame: 4years

  5. Change in 2h blood glucose, during an oral glucose tolerance test

    Change in 2h blood glucose (g/l), during an oral glucose tolerance test

    Time frame: 4 years

  6. Change of the insulin resistance index (HOMA-IR)

    Change of the insulin resistance index (HOMA-IR) from fasting parameters: from fasting insulin levels (mU/mL) and fasting blood glucose levels (mmol/L)

    Time frame: 4years

  7. Change of the insulin sensitivity index (HOMAβ)

    Change of the insulin sensitivity index (HOMAβ) from fasting parameters: from fasting insulinemia (mU/mL) and fasting blood glucose (mmol/L)

    Time frame: 4years

  8. Change in body weight (kg)

    Time frame: 4years

  9. Change in body mass index (kg/m2)

    Time frame: 4years

  10. Change in waist circumference (cm)

    Time frame: 4years

  11. Change in waist-to-hip ratio (without unit)

    Time frame: 4years

  12. Change in body composition

    Change in body composition (fat mass, lean mass, bone mass, muscle mass)

    Time frame: 4years

  13. Change in blood pressure

    Change in systolic and diastolic pressure (mmHg)

    Time frame: 4years

  14. Change in plasma lipid profile

    Liver and muscle lipid content will be measured by MRI.

    Time frame: 4years

  15. Change in muscle function

    Change in muscle function assessed by various tests, such as: Prehension strength: The value of the hand grip strength is measured with a dynamometer for 3 to 5 seconds by 3 measurements with each hand. The average of the 3 measurements for each hand will allow the dominant hand to be interpreted

    Time frame: 4 years

  16. Change in muscle function

    Change in muscle function assessed by various tests, such as: SPPB score: Assesses physical performance and distinguishes between people with severe disability (0-4 points), moderate or frail (4-6 points), mild or pre-frail (7-9 points), and those without significant disability or independent (10-12 points).

    Time frame: 4 years

  17. Change in visceral fat (kg)

    Time frame: 4 years

  18. Change in liver fat (kg)

    Time frame: 4 years

  19. Change in muscle fat (kg)

    Time frame: 4 years

  20. Change in muscle function

    Change in muscle function assessed by various tests, such as: TUG Score ( calculates the time it takes to get up from a chair without using your arms. A time \<10 seconds is normal; 10\>time\<20 is a marker of frailty; time \<20 seconds:the elderly person is at high risk of falling).

    Time frame: 4 years

  21. Change in muscle function

    Change in muscle function assessed by various tests such as: 6 min walk test: At the 6th minute, the operator also notes the level of dyspnea.

    Time frame: 4 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2029, 34 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 34 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 20, 2025
StartEst.
Sep 15, 2026
Primary completionEst.
Jul 15, 2029
CompletionEst.
Jul 15, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075133
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Sep 15, 2026 (estimated)
Primary completion
Jul 15, 2029 (estimated)
Completion
Jul 15, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

MONTASTIER Emilie, MD
Contact
montastier.e@chu-toulouse.fr
5 61 32 30 41 ext. +33
TOMASIK Audrey
Contact
tomasik.a@chu-toulouse.fr
5 61 77 85 97 ext. +33
MONTASTIER Emilie, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion